Single, postoperative IV dose of abelacimab superior to enoxaparin for preventing venous thromboembolism, with no increase in bleeding risk<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, July 26, 2021 (HealthDay News) — For patients undergoing total knee arthroplasty, abelacimab, a monoclonal antibody that binds to factor XI and locks it in the zymogen conformation, is effective for preventing venous thromboembolism without increasing the risk for bleeding, according to a study published online July 19 in the New England Journal of Medicine<\/em> to coincide with the annual congress of the International Society on Thrombosis and Haemostasis, held virtually from July 17 to 21.<\/p>\n Peter Verhamme, M.D., from Katholieke Universiteit Leuven in Belgium, and colleagues conducted an open-label trial involving 412 patients undergoing total knee arthroplasty who were randomly assigned to one of three regimens of abelacimab (30, 75, or 150 mg) administered postoperatively in a single intravenous dose or to once-daily enoxaparin administered subcutaneously. The primary efficacy outcome was venous thromboembolism; the principal safety outcome was a composite of major or clinically relevant nonmajor bleeding up to 30 days following surgery.<\/p>\n The researchers found that venous thromboembolism occurred in 13, 5, and 4 percent of patients in the 30-, 75-, and 150-mg abelacimab groups, respectively, compared with 22 percent in the enoxaparin group. The 30-mg abelacimab group was noninferior to enoxaparin, while superiority was demonstrated for the 75- and 150-mg abelacimab regimens versus enoxaparin. In the 30-, 75-, and 150-mg abelacimab groups, bleeding occurred in 2, 2, and 0 percent of patients, respectively, while there were no cases of bleeding observed in the enoxaparin group.<\/p>\n “Abelacimab reduced the risk of postoperative thromboembolism to a greater extent than conventional anticoagulants such as enoxaparin, without increasing the risk of bleeding,” the authors write.<\/p>\n Several authors disclosed financial ties to Anthos Therapeutics, which manufactures abelacimab and funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n